All In Biotech

Drug Trial Radar · NCT07752264

A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy

An Open-label, Single-arm Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Equecabtagene Autoleucel Injection (Eque-cel) in Subjects With Immune-mediated Necrotizing Myopathy

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Aug 15, 2026

Primary completion

Aug 15, 2030

Study completion Aug 15, 2043

Sponsor

Sponsor type
Industry
First posted
Aug 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm Phase I/II clinical study to evaluate the efficacy and safety of Eque-cel Injection in patients with refractory immune-mediated necrotizing myopathy.

Conditions

  • Refractory Immune-mediated Necrotizing Myopathy

Interventions

  • Equecabtagene Autoleucel Injection (Eque-cel)Drug

    Eque-cel is a personalized, BCMA-targeted gene-modified autologous T-cell immunotherapy product capable of recognizing and eliminating both malignant and normal cells expressing BCMA. The CAR specifically identifies BCMA via a fully human single-chain variable fragment (scFv) with low immunogenicity, activates, proliferates, secretes cytokines, and kills target cells through the CD3ζ domain, while enhancing CAR-T expansion and persistence via 4-1BB costimulation signaling. Eque-cel demonstrates high affinity for the BCMA antigen both in vitro and in vivo, as well as efficient killing of antigen-loaded cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Safety endpoint - Adverse Events (AEs)Time frame: up to 2 years from Eque-cel Injection infusion
  2. Phase I: Safety endpoint-incidence of Dose-limiting toxicity (DLT)Time frame: Time Frame: up to 28 days from Eque-cel Injection infusion
  3. Phase II: Efficacy endpoint- TIS responseTime frame: up to the 2 years after Eque-cel Injection infusion

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Huashan Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.